Immunotherapy After Radiotherapy in Elderly ESCC
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age75+
SponsorThe Central Hospital of Lishui City
About this trial
The incidence and mortality of esophageal squamous cell carcinoma are at the forefront in China.Most part of patients are elderly. Concurrent chemoradiotherapy is the standard treatment for unresectable locally advanced esophageal squamous cell carcinoma. Most elderly patients cannot tolerate concurrent chemotherapy because of complications and other reasons. Immunotherapy has definite efficacy and low toxicity in advanced esophageal squamous cell carcinoma, and the results combined with radiotherapy have also been preliminarily reported. Therefore, it is necessary to further explore the efficacy and safety of radiotherapy combined with immunotherapy in elderly patients with esophageal squamous cell carcinoma.
Eligibility criteria
Qualifiers
Age ≥75 years old, regardless of gender；
Esophageal cancer confirmed by histology or cytology；
Unresectable, unable to tolerate or refuse surgery and concurrent chemoradiotherapy；
Unable to tolerate chemotherapy；
Disqualifiers
Synchronous or metachronous second primary malignancy. Participants with basal cell carcinoma of the skin, or cervical cancer in situ that have undergone potentially curative therapy are not excluded from the study;
with multifocal primary esophageal cancer;
The pathological diagnosis was esophageal small cell carcinoma, adenocarcinoma, or mixed carcinoma.
Esophageal squamous cell carcinoma with active bleeding within 2 months of the primary lesion；
Trial design
Treatments tested in this trial
- Radiotherapy
- Toripalimab
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov